Open
Do not take FILDENA if you take medicines called guanylate cyclase stimulators which include: Across all trials, FILDENA improved the erections of 43% of radical prostatectomy patients compared to 15% on placebo.

Do not take FILDENA if you take medicines called guanylate cyclase stimulators which include: Across all trials, FILDENA improved the erections of 43% of radical prostatectomy patients compared to 15% on placebo.

On a global improvement question, 83% of patients reported improved erections on FILDENA versus 12% on placebo. The changes from baseline in scoring on the two end point questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) were highly statistically significantly in favor of FILDENA. On a global improvement question, 57% of FILDENA patients reported improved erections versus 10% on placebo.

 

There were highly statistically significant improvements on the two principal IIEF questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) on FILDENA compared to placebo. As in the other titration studies, patients were started on 50 mg and allowed to adjust the dose up to 100 mg or down to 25 mg of FILDENA; all patients, however, were receiving 50 mg or 100 mg at the end of the study. FILDENA improved these aspects of sexual function: frequency, firmness and maintenance of erections; frequency of orgasm; frequency and level of desire; frequency, satisfaction and enjoyment of intercourse; and overall relationship satisfaction.

 

At the end of the long-term study, 88% of patients reported that FILDENA improved their erections. Sixty-three percent, 74%, and 82% of the patients on 25 mg, 50 mg and 100 mg of FILDENA, respectively, reported an improvement in their erections, compared to 24% on placebo. At the same time, on-treatment function was better in treated patients who were less impaired at baseline.

 

The primary measure in the principal studies was a sexual function questionnaire (the International Index of Erectile Function -IIEF) administered during a 4-week treatment-free run-in period, at baseline, at follow-up visits, and at the end of double-blind, placebo-controlled, at-home treatment. Given Cenforce peak plasma concentrations of approximately 1 μM after recommended doses, it is unlikely that FILDENA will alter the clearance of substrates of these isoenzymes. At 24 hours the plasma levels of Cenforce were still approximately 200 ng/mL, compared to approximately 5 ng/mL when Cenforce was dosed alone.

 

Population pharmacokinetic data from patients in clinical trials also indicated a reduction in Cenforce clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) see DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS. When a single 100 mg dose of FILDENA was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 160% increase in Cenforce Cmax and a 182% increase in Cenforce AUC. Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma Cenforce concentrations when co-administered with FILDENA (50 mg) to healthy volunteers.

 

Mean Cenforce plasma concentrations measured after the administration of a single oral dose of 100 mg to healthy male volunteers is depicted below: There was no effect on sperm motility or morphology after single 100 mg oral doses of FILDENA in healthy volunteers.
http://fildenaitalia.net/fildena-italia/fildena-effetti-collaterali.html
FaLang translation system by Faboba
top